

NEWSLETTER March – April 2019

CEO's greetings

Inspiring spring! We raised a successful funding round of about €5.8 million, exceeding our target. The round was led by Robur's global healthcare investment fund, Medica, whose Portfolio Manager Mattias Häggblom was subsequently [interviewed by BioStock](#) (in Swedish). Internally, the fund raising has been followed by strategizing our next steps including scaling-up of manufacturing processes, and the possible future clinical studies.

Our [Annual Report](#) was published. Read especially the very interesting interviews with Professor Per Svenningsson, the Principal Investigator in our Parkinson's study with CDNF; and with Kira Olenius, a research nurse in our lymphedema study with Lymfactin®.

CLINICAL STUDIES

- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE study is actively recruiting patients in Sweden and Finland. See [Lymfactin web site](#) for more information.
- **Parkinson's disease:** Phase 1–2 study with CDNF ongoing, not actively recruiting new patients.
- **Breast Cancer Associated Lymphedema:** Phase 1 study in long-term follow-up, not actively recruiting patients.

PLANNED ACTIVITIES

- **Aktiespararna, 14 May 2019 in Stockholm:** Company presentation to Swedish investors, preparing our possible dual listing in Nasdaq First North Stockholm later in 2019
- **BioEquity, 20–21 May 2019 in Barcelona:** Herantis will meet investors at Europe's main annual biotech investor event
- **Herantis presentation, 23 May 2019 in Helsinki:** Company presentation for the Investors' association of the Helsinki district
- **Interim report on Jan-Jun 2019: 28 Aug 2019**

'Herantis' of the month



Our CSO, Henri, presenting CDNF to a full 1,000-seat auditorium at AD/PD congress in Lisbon, Portugal. Part of the audience was left outside due to lack of space! Striking difference to Henri's previous AD/PD presentation to an audience of about 50.

Keep up-to-date on Herantis:



Highlights from our team

Sigrid, Director Clinical Development: "Device implantation surgery completed in 16 of the 18 patients in our Phase 1–2 Parkinson's study. Dose escalation will soon proceed to the highest planned dose levels with CDNF."

Satu, Project Manager: "Swedish sites opened, and the first Swedish patients already screened in our Phase 2 AdeLE study with Lymfactin®. Welcome Karolinska and Uppsala university hospitals!"

Topics of interest

In the United Kingdom, BBC aired a two-part documentary "**The Parkinson's Drug Trial: A Miracle Cure?**" covering a Phase 2 clinical study with GDNF in Parkinson's disease.

Despite the similar names Herantis' CDNF is mechanistically clearly distinct from GDNF. Our data presented at the AD/PD 2019 suggest that our CDNF is more potent than GDNF in a well-established disease-model of Parkinson's. However, both use the exact same route of administration; and both programs share the same dream: Breakthrough in the treatment of Parkinson's disease.

Herantis in the news

Nordic Life Science News' interview with Herantis' CEO can be found [here](#) (in English).

Edison Investment Research published a video interview and an interim report (in English), both available [here](#).

Scientific article published in the peer-reviewed medical journal Cell Transplantation: Huttunen & Saarma: [CDNF protein therapy in Parkinson's Disease](#).